News & and media
Inauguration of the new Montreal RNA T&T laboratories
June 12, 2024
Montreal, June 12, 2024 – RNA Technologies and Therapeutics is pleased to announce the inauguration of its new laboratories at the Institut de recherches cliniques de Montréal (IRCM) / Montreal Clinical Research Institute, a pillar of research and clinical care located in the heart of the Quebec metropolis.
Many guests, government dignitaries, and stakeholders from the university research community attended the official opening.
“The IRCM is pleased to welcome RNA T&T for fruitful collaborations in population health,” said Dr. Jean-François Côté, President and Scientific Director of the IRCM
“We warmly thank the IRCM for welcoming and supporting the integration of RNA T&T into their facilities, a center of excellence in genetic research and personalized medicine. We would also like to express our gratitude to all our collaborators who have supported and accelerated the growth of RNA T&T since its inception in July 2022. Special thanks are due to the National Research Council Canada / Conseil national de recherches Canada, NRC Royalmount site, the Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) and the CQDM for their research and development support programs, as well as Innovation, Science and Economic Development Canada, BDC – Banque de développement du Canada, Investissement Québec and RBC for funding the purchase of equipment for start-ups like ours. We also highlight the work of BIOQuebec and Montréal InVivo in supporting the entire biotechnology sector and promoting it to governments, and we finally thank the CQIB, Quebec Life Sciences Incubator & Accelerator incubator in Laval and District 3 Innovation in Concordia University for their hosting and support through their respective programs for start-ups,” said Mr. Claude LeDuc, President and CEO of RNA T&T.
About RNA T&T
RNA T&T specializes in designing, producing, optimizing and encapsulating premium messenger RNA in lipid nanoparticles. RNA T&T also offers co-development services for therapeutic targets based on RNA technologies to researchers at academic institutions and biotechnology companies.
RNA (ribonucleic acid) represents a revolutionary advancement in biotechnology, offering immense potential for developing new therapies. With its unique ability to regulate gene expression and code for therapeutic proteins, RNA is paving the way for innovative treatments for many diseases, ranging from viral infections to cancers to genetic diseases. RNA-based therapies, such as mRNA vaccines, have already demonstrated their effectiveness and speed of development, promising a new era of personalized medicine and targeted healing. RNA Technologies & Therapeutics (RNA T&T) Inc. is at the forefront of innovation in RNA technologies, striving to provide advanced and collaborative solutions for developing new technologies.
